Background and Purpose-The complexity and heterogeneity of stroke, as well as the associated comorbidities, may render neuroprotective drugs less efficacious in clinical practice. Therefore, the development of targeted therapies to specific patient subsets has become a high priority in translational stroke research. Ischemic stroke with type 2 diabetes mellitus has a nearly double mortality rate and worse neurological outcomes. In the present study, we tested our hypothesis that rFGF21 (recombinant human fibroblast growth factor 21) administration is beneficial for improving neurological outcomes of ischemic stroke with type 2 diabetes mellitus. Methods-Type 2 diabetes mellitus db/db and nondiabetic genetic control db/+ mice were subjected into permanent focal ischemia of distal middle cerebral artery occlusion, we examined the effects of poststroke administration with rFGF21 in systemic metabolic disorders, inflammatory gatekeeper PPARγ (peroxisome proliferator-activated receptor γ) activity at 3 days, mRNA expression of inflammatory cytokines and microglia/macrophage activation at 7 days in the perilesion cortex, and last neurological function deficits, ischemic brain infarction, and white matter integrity up to 14 days after stroke of db/db mice. Results-After permanent focal ischemia, diabetic db/db mice presented confounding pathological features, including metabolic dysregulation, more severe brain damage, and neurological impairment, especially aggravated proinflammatory response and white matter integrity loss. However, daily rFGF21 treatment initiated at 6 hours after stroke for 14 days significantly normalized systemic metabolic disorders, rescued PPARγ activity decline, inhibited proinflammatory cytokine mRNA expression, and M1-like microglia/macrophage activation in the brain. Importantly, rFGF21 also significantly reduced white matter integrity loss, ischemic brain infarction, and neurological function deficits up to 14 days after stroke. The potential mechanisms of rFGF21 may in part consist of potent systematic metabolic regulation and PPARγ-activation promotion-associated antiproinflammatory roles in the brain. Conclusions-Taken together, these results suggest rFGF21 might be a novel and potent candidate of the disease-modifying strategy for treating ischemic stroke with type 2 diabetes mellitus. Visual Overview-An online visual overview is available for this article.
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December 2018 activator) therapy because of the higher risk of hemorrhagic transformation. 4, 5 All diabetic stroke patients present poststroke hyperglycemia and other metabolic disorders. 6 From a translational perspective, development of new compounds with multiple pharmacological functions, particularly targeting T2D stroke-related metabolic dysregulation, ischemic brain damage, and detrimental proinflammation, called diseasemodifying approaches, would be novel and more effective for treating ischemic stroke with T2D.
7 FGF21 (fibroblast growth factor 21) might be one of the optimal therapeutic candidates.
FGF21 is an endocrine member of the FGF family. It has a potent and central role in glucose and lipid metabolism, as well as in energy balance. 8 Human FGF21 (molecular weight, 19.5 kD) is highly homologous to mouse FGF21 (≈75% identity). 9 The very low heparin-binding affinity makes FGF21 capable of crossing the blood-brain barrier by simple diffusion. 10 FGF21 exerts potent and multipleiotropic metabolic actions, 11, 12 with benefits that have been translated from rodents to obese humans with T2D without causing side effects, such as mitogenicity and hypoglycemia. 13, 14 Growing experimental findings have demonstrated FGF21 is also a mediator of adaptive responses to tissue injury and repair in various pathological conditions. 12, 15, 16 In the present study, we propose that FGF21 is a novel therapeutic candidate with both adaptive and protective pharmacological actions that protect against both metabolic and stroke stresses in T2D, that result in improvement of neurological outcomes. Using T2D animal model, db/db mice, and nondiabetic genetic control db/+ mice, we tested our hypothesis that rFGF21 (recombinant human FGF21) administration is beneficial for improving neurological outcomes of T2D stroke mice. Our experimental results are highly supportive to the hypothesis and demonstrate that rFGF21 might be developed as a novel and potent disease-modifying approach for treating ischemic stroke with T2D.
Methods
Details of materials and experimental procedures are available in the online-only Data Supplement. The data that support the findings of this study are available from the corresponding author on reasonable request.
Focal Ischemia Stroke Animal Model and Experimental Groups
Ten weeks old male BKS.Cg-Dock7m +/+ Lepr db/J homozygous (db/db) mice, weighing 40 to 50 g, and their age-matched nondiabetic counterparts BKS-Cg-Dock7m +/+ Lepr db/J heterozygous (db/+) mice, weighing 25 to 30 g, were purchased from Jackson Laboratory. Focal ischemic stroke was achieved with coagulation of the distal middle cerebral artery, followed by 90 minutes bilateral common carotid artery ligation as previously described with slight modifications. 17 Animals were subcutaneously administrated with either 1.5 mg/kg recombinant FGF21 or saline initiated at 6 hours after stroke, followed by twice daily subcutaneous injections (1.5 mg/kg per time) with an interval of 10 to 12 hours for up to 14 days. All experiments were performed after protocols approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee in compliance with the NIH Guide for the Care and Use of Laboratory Animals. All experimental assessments were performed by investigators who were blind to the experimental groups.
Measurements of Body Weight, Blood
Glucose, HbA1c (Glycated Hemoglobin), Insulin, and Adiponectin Levels Details are provided in the online-only Data Supplement.
Neurobehavioral Assessments
The following sensorimotor function deficits were assessed before and poststroke day 1, 3, 5, 7, and 14. (1) Adhesive removal test result was represented by the time-to-contact and time-to-remove of each forepaw that was recorded, respectively as previously described. 18 (2) Grip strength test result was quantified as percentage of each individual preischemic baseline as previously described. 19 (3) Foot fault test result was quantified as percentage of foot faults referring to the total steps as previously described. 20 Additionally, cognitive function deficit was assessed at poststroke day 14 by Y-maze test and quantified with the percentage of alternations as we previously described.
21

Reverse Transcription and Real-Time Polymerase Chain Reaction Assay
Peri-infarct cortical tissues or corresponding cortical tissues in shamoperated group were collected at 7 days after stroke and stored at −80°C until processing. Total RNA was extracted using RNeasy Lipid Tissue Mini Kit (Qiagen), and real-time polymerase chain reaction was performed as we previously described. Further details are provided in the online-only Data Supplement.
Measurement of PPARγ (Peroxisome Proliferator-Activated Receptor γ) Activity With Electrophoretic Mobility Shift Assay (EMSA)
We performed electrophoretic mobility shift assay by following a standard protocol as we previously described. 22 Further details are provided in the online-only Data Supplement.
Measurements of Brain Infarction and Axon Myelination Level
At 14 days after stroke, brain sections were stained with hematoxylin & eosin for quantifying ischemic brain infarction size as we previously described. 23 Axon myelination level was detected with the luxol fast blue staining and quantified as previously described with slight modification. 24 Briefly, myelination levels of external capsule were evaluated using quantitative scoring method. It assigned 4 for mice with the sham operation (having normal myelin levels in external capsule area), whereas a fully demyelinated external capsule area was given a score of 0. Sections were measured and scored by 2 independent individuals who were blinded to the experimental group assignment.
Immunohistochemistry Analysis
Immunohistochemistry was conducted using the standard protocol as we described previously. 21 Further details are provided in the onlineonly Data Supplement. After a stroke, db/db mice maintained stable hyperglycemia (but body weight was not altered), had an elevated blood HbA1c level, hyperinsulinemia, and lowered serum adiponectin level (Figure 1 ). However, rFGF21 treatment significantly reduced blood glucose level by ≈63% reduction ( Figure 1A ) and lowered HbA1c level from 8.9% to 7.1% ( Figure 1B) . The poststroke hyperinsulinemia was also significantly diminished by rFGF21 treatment (71% reduction; Figure 1C) . Moreover, the stroke-induced lower serum adiponectin level was significantly rescued by rFGF21 treatment (60% increase; Figure 1D ). These data suggest that rFGF21 has potent therapeutic effects for metabolic improvement in hyperglycemia, poststroke hyperinsulinemia, and hypoadiponectinemia of db/db stroke mice. In a separate experiment, we also tested rFGF21 effects in nondiabetic db/+ mice. There was no significant difference in both blood glucose levels and body weight of nondiabetic db/+ mice after ischemic stroke between rFGF21 treated and nontreated group, and rFGF21 did not cause hypoglycemia, indicating a relative safe profile of rFGF21 administration after stroke ( Figure I in the onlineonly Data Supplement).
Statistical Analysis
rFGF21 Attenuates Neurological Function Deficits and Reduced Ischemic Brain Lesion Size in Diabetic db/db Mice After Focal Stroke
As expected, both db/+ stroke mice and db/db stroke mice showed significant deficits up to 14 days after stroke. The sensorimotor function deficits in db/db stroke mice were significantly worse than the nondiabetic db/+ stroke mice. Most importantly, rFGF21 treatment dramatically attenuated 
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December 2018 deficits in all 3 sensorimotor function tests of db/db stroke mice ( Figure 2A ). The db/db sham mice were prone to motionlessness or moved slowly in Y-maze test. At 14 days after stroke, the further reduced total number of arm entries and lowered alternation ratio in db/db mice were all significantly rescued by rFGF21 treatment ( Figure 2B ). These results suggest a potent therapeutic potential of rFGF21 treatment for improving neurological functions after ischemic stroke in T2D. Ischemic brain infarct size was measured at 14 days after stroke. The db/db stroke mice had a significantly larger infarct (6.6% of contralateral side) compared with the db/+ stroke mice (2.1% of contralateral side), excitingly rFGF21 significantly reduced infarct size of db/db stroke mice (44.1% reduction; Figure 2C ). We also found the third coronal section (+1.3 mm from bregma) represented the location of maximal cortical change in infarction after rFGF21 treatments; thus the third coronal section was selected for histological analysis in this study ( Figure 2D ). There was no mortality in all stroke groups.
We also tested the effects of rFGF21 in neurological outcomes and ischemic brain lesion size of nondiabetic db/+ mice. rFGF21 treatment did not alter neurological functions up to 14 days after stroke ( Figure IIA in the online-only Data Supplement), while slightly reduced brain infarction size in nondiabetic db/+ mice (12.5% reduction), but it was not statistically significant ( Figure IIB and IIC in the online-only Data Supplement).
rFGF21 Enhances Nuclear Transcriptional Factor PPARγ DNA-Binding Activity in Diabetic db/db Mice After Focal Stroke
The PPARγ DNA-binding activity was significantly decreased at 3 days after stroke in both db/+ stroke (36.6% reduction) and db/db stroke mice (41.1% reduction). Importantly, rFGF21 significantly promoted the PPARγ DNA-binding activity of db/db mice (34% increase; Figure 3 ). These results demonstrate the dampened PPARγ activity in db/db mouse brains after stroke can be significantly elevated by poststroke administration of rFGF21.
rFGF21 Suppresses Proinflammatory Cytokine Expression in Perilesion Cortex of Diabetic db/db Mice After Focal Stroke
At 7 days after stroke, mRNA expression of inflammatory genes in the cortical perilesion area was examined by realtime polymerase chain reaction. We did not detect any significant differences between db/+ sham and db/db sham mice ( Figure 4 ). However, in 4 selected proinflammatory genes, ischemic stroke only significantly increased TNF-α (tumor necrosis factor-α) and CCL (C-C motif chemokine ligand) 3 mRNA expression in db/+ mice. While in db/db stroke mice, all 4 proinflammatory genes TNF-α, IL (interleukin)-1β, TLR (Toll-like receptor) 4, and CCL3 mRNA expressions exhibited significantly higher levels, suggesting more dominant proinflammatory response in the ischemic brain of db/db stroke mice. Importantly, rFGF21 treatment significantly reduced the stroke-elevated proinflammatory gene mRNA expressions, demonstrating a potent inhibiting effect for proinflammation in the ischemic brain of T2D db/db mice ( Figure 4A ). In contrast, ischemic stroke significantly increased 4 anti-inflammatory cytokines or trophic factors mRNA levels for IL-4, IL-10, IGF (insulin like growth factor) 1, and TGF (transforming growth factor)-β in both db/+ and db/db mice. Interestingly, there was a significant lower mRNA expression of IL-4 and IL-10 in the db/db stroke mice compared with db/+ stroke mice. Importantly, rFGF21 treatment to the db/db stroke mice significantly upregulated all 4 selected mRNA expressions of IL-4, IL-10, IGF-1, and TGF-β ( Figure 4B ). These data suggested there might be an impairment of anti-inflammatory and neurorepair responses in the db/db mouse brains after stroke, which may be significantly restored by rFGF21 treatment. Figure 5A and 5B) In the subcortex striatum areas, Iba-1 positive cell number was significantly increased in both db/+ and db/db stroke mice, but significantly higher Iba-1/CD16 double positive cells were only detected in db/ db stroke mice. The increase in Iba-1/CD16 double positive cells can be significantly reduced by rFGF21 treatment ( Figure 5C ). Next, we determined M2-like anti-inflammatory microglia/macrophage by counting Iba-1/CD206 double positive cells. There were very low levels of Iba-1/CD206 double positive cells, and no significant differences could be detected between groups. However, rFGF21 treatment significantly increased the Iba-1/CD206 double positive cells in perilesion cortex of db/db stroke mice ( Figure 5D ). These results further demonstrated a distressed proinflammatory response in the brain of db/db stroke mice; suppressing M1-like microglia/ macrophage activation might be one of the anti-detrimental neuroinflammation mechanisms of rFGF21. 
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White matter integrity after stroke was examined at 14 days after stroke. Axonal injury was examined by immunohistochemistry of MBP (myelin basic protein) expression, and myelination score was determined by luxol fast blue staining at perilesion external capsule. Ischemic stroke significantly decreased more MBP expression (MBP loss) in db/db mice than db/+ mice, however, we only detected a significant decrease of myelination score in db/db stroke mice. Importantly, rFGF21 significantly rescued MBP expression decrease ( Figure 6A and 6C) and elevated myelination score in db/ db stroke mice ( Figure 6B and 6D) . These results suggest an aggravated white matter integrity loss in db/db stroke mice, where rFGF21 significantly promoted white matter integrity by attenuating the axonal injury while promoting myelination, which might be in part responsible to the improved neurological outcomes.
Discussion
The major findings of the present experiments can be summarized that (1) compared with nondiabetic db/+ mice, diabetic db/db mice presented some of confounding pathological features of ischemic stroke, including metabolic dysregulation, more severe brain damage, and neurological impairment, and in particular aggravated proinflammatory response and white matter integrity loss. (2) The db/db mice that received rFGF21 at 6 hours after stroke for 14 days showed significantly normalized systemic metabolic disorders, rescued anti-inflammatory gatekeeper PPARγ activity, inhibited proinflammatory cytokines mRNA expression and microglia/macrophage activation after stroke in the perilesion cortex. (3) The rFGF21 administration also significantly reduced white matter integrity loss, ischemic brain infarction, and neurological function deficits up to 14 days after stroke. These results demonstrate that rFGF21 might be a novel and potent candidate of the diseasemodifying approach for treating ischemic stroke with T2D. The most unique biological feature of FGF21 is its ability to exert potent and multipleiotropic metabolic effects, 11, 12 such as improvements in hyperglycemia, insulin resistance, lipid profiles, and adiponectin production in obese and diabetic animals. [25] [26] [27] We found db/db stroke mice presented hyperglycemia, elevated poststroke hyperinsulinemia, and hypoadiponectinemia, each of these metabolic disorders has been demonstrated independently to be associated with poor clinical outcome after stroke. 28 Importantly, rFGF21 treatment, even when initiated at 6 hours after stroke remarkably eliminated these metabolic dysregulations. These potent metabolic modulation effects of rFGF21 may be one of its beneficial mechanisms for improving neurological outcomes after stroke in the db/db mice.
It is important to determine whether this endocrine regulator rFGF21 is beneficial or might cause detrimental hypoglycemia to the ischemic stroke control of nondiabetes mellitus. Experimental results showed there were no hypoglycemia and body weight decline during the 14 days treatment period of rFGF21 after stroke. Furthermore, rFGF21 treatment did not significantly alter neurological functions but slightly reduced brain infarct size. These results suggest that rFGF21 is relatively safe and does not induce hypoglycemia. However, the neutral results of rFGF21 treatment in long-term outcomes of nondiabetes mellitus stroke mice might be in part because of the relatively smaller infarction and mild neurological deficits of the distal middle cerebral artery occlusion model, and relatively smaller sample size applied in the current study. 29 The precise roles and mechanisms of rFGF21 in ischemic stroke outcomes of nondiabetes mellitus need to be fully investigated in future experiments, including other ischemic stroke animal models. Importantly, in contrast to the protective effects of rFGF21 in T2D db/db stroke mice, these results obtained from nondiabetic mice are also supportive to our hypothesis that rFGF21 is a novel and specific disease-modifying approach for treating ischemic stroke with T2D.
We next explored the effects and potential mechanisms of rFGF21 in the brain of diabetic stroke mice. It has been known that a very low heparin-binding affinity makes FGF21 capable of crossing the blood-brain barrier by simple diffusion. 10 Our previous study showed subcutaneous injection with rFGF21 significantly increased its concentration in cerebrospinal fluid, and phospho-FGFR (fibroblast growth factor receptor) 1 levels in mouse brain tissues, demonstrating rFGF21 could cross blood-brain barrier and functionally activate FGF21-FGFR1 signaling in the brain. 21 Interestingly, FGF21 has been reported as a key mediator involving in the physiological and pharmacological actions of PPARγ. 30 PPARγ is a nucleus receptor that transcriptionally regulates gene expressions, especially functions as a master gatekeeper of cytoprotective stress response in brain injury and repair after stroke mainly by suppressing proinflammatory and neurodegenerative responses. 31 Because ischemic stroke in diabetic animals may exacerbate or sustain the proinflammatory response, 5,32 thus we measured early transcriptional regulator PPARγ activity at 3 days after stroke, yet examined its downstream signaling pathways microglia/macrophage activation, and expression of inflammatory factors in the brain at late 7 days after stroke in T2D db/ db mice. However, the precise temporal causal relationship between PPARγ activity and inflammatory factor expression remains to be carefully elucidated.
We found a significant decrease of PPARγ DNA-binding activity at 3 days after stroke in perilesion cortex of T2D mice, but it was significantly elevated by poststroke administration of rFGF21. Although as a transcriptional factor, how the rFGF21-activated PPARγ regulate its targeting signaling pathways remain to be elucidated; accumulating experimental evidence have supported the critical roles of PPARγ activity for improving the chances of cellular survival and recovery of homeostatic equilibrium after ischemic stroke. 31 PPARγ functions as a major transcriptional factor that inhibits proinflammatory responses after ischemic stroke. 31 Experimental evidence has demonstrated that in acute and subacute phase after ischemic stroke, the higher proinflammatory or lower anti-inflammatory cytokine expression profiles represent a relatively more detrimental environment in the ischemic brain that might contribute to the secondary brain tissue damage and neurorepair impairment after stroke. 32 Our experimental data showed highly elevated M1-like proinflammatory microglia/macrophage activation in the brain of T2D db/db mice after stroke, which is consistent with the increased mRNA expression of proinflammatory cytokines. Importantly, the potent effects of rFGF21 on inhibition of proinflammatory cytokine mRNA expression and M1-like microglia/macrophage activation, and elevation of anti-inflammatory gene mRNA expression, facilitate a strong antineuroinflammation role, and may be one of key underlying mechanisms for improving neurological outcomes in T2D stroke. The antineuroinflammation action of rFGF21, might be in part because of PPARγ activation promotion.
However, we can not exclude the possibility that rFGF21 might be able to suppress systemic inflammation and brain infiltration of inflammatory cells in diabetic stroke mice, thereby contribute to the promotion of neurological function recovery. Since in our previously published study, we showed rFGF21administration significantly reduced mRNA levels of proinflammatory cytokines IL-1β, IL-6, and TNF-α in white adipose tissue, and completely eliminated the elevated blood plasma cytokine levels of TNF-α and IL-1β, demonstrating a potent antisystemic inflammation effect of rFGF21 in the high-fat diet consumption induced obese mouse model. 21 However, this systemic anti-inflammatory effects and mechanisms of rFGF21 in focal ischemic stroke of T2D warrant further investigation.
Interestingly, white matter injury induced by ischemic stroke inside and beyond stroke lesions is one of the clinically pathological features of T2D, which has been considered one of the key mechanisms for worse stroke damage and poorer recovery. 33 A previous experimental study showed PPARγ activation by rosiglitazone treatment that facilitated microglial polarization toward the beneficial M2 phenotype, was considered at least in part, a contributor to the improvement of white matter integrity after cerebral ischemia in mice. 34 Importantly, we found rFGF21 significantly promoted white matter integrity by attenuating the axonal injury and increase myelination levels, which might be partially contributed to rFGF21 treatment-mediated PPARγ activation and one of important underlying mechanisms for the improved neurological outcomes.
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Although our experimental findings are both fundamentally and translationally significant, several limitations still exist. First, in this study, we used C57BLKS-Leprdb T2D mice (db/db T2D mice, Jackson Lab). We are aware that although the leptin receptor mutation does not reflect disease cause in humans, this model has already given us insight into glucose metabolism and identified novel pathways of its complications. 35 However, there are variable pathogenic mechanisms between different T2D animal models 36 ; testing rFGF21 in other animal models of diabetes with ischemic stroke should be pursued in the future. Second, in the present study, we only tested rFGF21 effects in PPARγ activation, cytokine mRNA expression, and microglia/macrophage activation after focal stroke of T2D mice. However, our results suggested that rFGF21-mediated PPARγ activation might in part contribute to the proinflammatory inhibition in the brain of T2D mice. The causal relation and significance of the rFGF21-PPARγ activation in modulating neuroinflammation of T2D stroke need to be defined by pharmacological and genetic approaches in future investigation. Third, there are multiple pathological factors that dynamically and interactively participate in T2D stroke brain damage evolution and recovery processes. 32 Thus, it would be important to understand how rFGF21 may pharmacologically modulate these individual pathological mechanisms of tissue injury and repair, which requires more investigations. 37 Moreover, we acknowledge that it is likely impossible to truly separate each mechanism or signaling pathway of rFGF21, however, the multitargeted property of rFGF21 might be a translational strength. 15 Fourth, because of lack of available working antibody for immunohistochemistry to detect the active form of FGF21 receptor FGFR1 (phosphorylation-FGFR1), we were unable to define brain regions and cellular types for FGF21-FGFR1 activation that taking place, however, spatial and time profile of exogenous FGF21-mediated receptor activation and consequent biological signaling pathways in the context of neurovascular unit warrant further investigation. 38 Fifth, because stroke patients while in hospital are treated with glucoselowering medications, it would be important to have them as rFGF21 controls, which was missing in present study. New experiments including the glucose-lowering medication controls would be informative to gain a broader cross-comparison of clinically relevant antidiabetic agent. Last, this study was proposed as a proof-of-concept investigation, all translational aspects, include using FGF21 analog, testing, and comparing both male and female animals, should be further tested in a well-controlled preclinical translational setting. 14, 37 In conclusion, we demonstrate rFGF21 administration is beneficial for improving neurological outcomes in T2D stroke mice. The potential mechanisms are, at least in part, by systemic metabolic modulation, brain tissue PPARγ activationmediated proinflammation inhibition, and whiter matter integrity promotion. rFGF21 might be developed as a novel and potent disease-modifying approach for treating ischemic stroke with T2D.
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